EA201590684A1 - Новые соединения - Google Patents

Новые соединения

Info

Publication number
EA201590684A1
EA201590684A1 EA201590684A EA201590684A EA201590684A1 EA 201590684 A1 EA201590684 A1 EA 201590684A1 EA 201590684 A EA201590684 A EA 201590684A EA 201590684 A EA201590684 A EA 201590684A EA 201590684 A1 EA201590684 A1 EA 201590684A1
Authority
EA
Eurasian Patent Office
Prior art keywords
integer
alkyl
compounds
useful
treatment
Prior art date
Application number
EA201590684A
Other languages
English (en)
Other versions
EA028480B1 (ru
Inventor
Дайан Мери Коу
Стивен Аллан Смит
Original Assignee
ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛАКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛАКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201590684A1 publication Critical patent/EA201590684A1/ru
Publication of EA028480B1 publication Critical patent/EA028480B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Соединения формулы (I) и их солигде Rпредставляет собой н-Cалкил или CалкоксиСалкил-; Rпредставляет собой водород или метил; каждый Rпредставляет собой гидрокси, галоген или н-Салкил; m означает целое число, имеющее значение от 2 до 4; n означает целое число, имеющее значение от 0 до 3; и р означает целое число, имеющее значение от 0 до 2, являются индукторами интерферона человека. Соединения, которые индуцируют интерферон человека, могут быть полезны в лечении различных расстройств, например в лечении аллергических заболеваний и других воспалительных состояний, например аллергического ринита и астмы, инфекционных заболеваний и рака, и могут быть также полезны в качестве вакцинных адъювантов.
EA201590684A 2012-11-20 2013-11-18 Новые соединения EA028480B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728390P 2012-11-20 2012-11-20
US201361774087P 2013-03-07 2013-03-07
PCT/US2013/070472 WO2014081645A1 (en) 2012-11-20 2013-11-18 Novel compounds

Publications (2)

Publication Number Publication Date
EA201590684A1 true EA201590684A1 (ru) 2016-03-31
EA028480B1 EA028480B1 (ru) 2017-11-30

Family

ID=50776485

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590684A EA028480B1 (ru) 2012-11-20 2013-11-18 Новые соединения

Country Status (32)

Country Link
US (3) US9540383B2 (ru)
EP (1) EP2922549B1 (ru)
JP (1) JP6228223B2 (ru)
KR (1) KR20150085055A (ru)
CN (1) CN104780922B (ru)
AU (1) AU2013348218B2 (ru)
BR (1) BR112015011400A8 (ru)
CA (1) CA2892218A1 (ru)
CL (1) CL2015001342A1 (ru)
CR (1) CR20150268A (ru)
CY (1) CY1119557T1 (ru)
DK (1) DK2922549T3 (ru)
DO (1) DOP2015000121A (ru)
EA (1) EA028480B1 (ru)
ES (1) ES2639789T3 (ru)
HK (1) HK1208826A1 (ru)
HR (1) HRP20171150T1 (ru)
HU (1) HUE13857477T2 (ru)
IL (1) IL238800B (ru)
LT (1) LT2922549T (ru)
ME (1) ME02867B (ru)
MX (1) MX358025B (ru)
NZ (1) NZ707319A (ru)
PE (1) PE20151086A1 (ru)
PH (1) PH12015501100B1 (ru)
PL (1) PL2922549T3 (ru)
PT (1) PT2922549T (ru)
RS (1) RS56233B1 (ru)
SG (1) SG11201503282RA (ru)
SI (1) SI2922549T1 (ru)
UA (1) UA114645C2 (ru)
WO (1) WO2014081645A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (ru) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Производные пурина для применения в лечении аллергий, воспалительных и инфекционных заболеваний
RU2631482C2 (ru) 2011-07-22 2017-09-22 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Композиция
CA2880576A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
BR112015011447A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto
EP2922547B1 (en) 2012-11-20 2017-03-08 Glaxosmithkline LLC Novel compounds
PT2922549T (pt) 2012-11-20 2017-09-01 Glaxosmithkline Llc Novos compostos
EP3107915B1 (en) 2014-02-20 2017-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
CN106661034B (zh) * 2014-08-15 2019-11-29 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
TWI558709B (zh) * 2015-10-07 2016-11-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
US10676478B2 (en) * 2015-11-05 2020-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
WO1997049706A1 (en) * 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IL150594A0 (en) 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
CN101016296A (zh) 2000-04-28 2007-08-15 阿卡蒂亚药品公司 毒蕈碱性激动剂
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US6713241B2 (en) 2002-08-09 2004-03-30 Eastman Kodak Company Thermally developable emulsions and imaging materials containing binder mixture
BRPI0313664B8 (pt) 2002-08-21 2021-05-25 Albert Einstein College Medicine Yeshiva Univ compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos
BR0314761A (pt) 2002-09-27 2005-07-26 Sumitomo Pharma Composto de adenina e seu uso
EP1646614A4 (en) 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
EP1667694B1 (en) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
UY28506A1 (es) 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
MY146124A (en) 2003-10-03 2012-06-29 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
UA89493C2 (ru) 2004-04-02 2010-02-10 Оси Фармасьютикалз, Инк. 6,6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
EP1915377A1 (en) 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
US7803828B2 (en) 2005-08-25 2010-09-28 Schering-Plough Corporation Functionally selective alpha2C adrenoreceptor agonists
CN101253173A (zh) 2005-09-02 2008-08-27 辉瑞有限公司 羟基取代的1h-咪唑并吡啶和方法
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
EP1939199A4 (en) 2005-09-22 2010-10-20 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
JPWO2007034916A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
GB2438679A (en) 2006-05-31 2007-12-05 Sra Dev Ltd Ultrasonic surgical tool having two modes of vibration
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
PT2038290E (pt) 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
TW200843779A (en) 2007-02-19 2008-11-16 Smithkline Beecham Corp Compounds
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
ATE530549T1 (de) 2007-03-19 2011-11-15 Astrazeneca Ab 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7)
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
CN101784548B (zh) 2007-06-29 2013-07-17 吉里德科学公司 嘌呤衍生物及其作为toll样受体7的调节剂的用途
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
MX2010001650A (es) 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
ITMO20080210A1 (it) 2008-08-01 2010-02-02 Marco Seghedoni Veicolo per il sollevamento e la movimentazione di manufatti
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
EA201100114A1 (ru) 2008-08-11 2011-10-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
EP2326646B1 (en) 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
UA103195C2 (ru) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Производные пурина для применения в лечении аллергий, воспалительных и инфекционных заболеваний
KR101616396B1 (ko) 2008-08-11 2016-04-28 글락소스미스클라인 엘엘씨 신규의 아데닌 유도체
CN102548999A (zh) 2009-01-20 2012-07-04 山东轩竹医药科技有限公司 含有取代的含氮稠杂环的头孢菌素衍生物
EP2454263B1 (en) * 2009-07-17 2018-06-13 Albert Einstein College of Medicine, Inc. 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
EA023536B1 (ru) 2009-08-07 2016-06-30 Глаксосмитклайн Байолоджикалс Са Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
PT2534149E (pt) 2010-02-10 2014-12-23 Glaxosmithkline Llc Maleato de 6-amino-2-{[(1s)-1-metilbutil]oxi}-9-[5-(1- piperidinil)pentil]-7,9-di-hidro-8h-purin-8-ona
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
US9139590B2 (en) * 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
ES2583877T3 (es) * 2011-06-01 2016-09-22 Janus Biotherapeutics, Inc. Moduladores novedosos del sistema inmunitario
RU2631482C2 (ru) 2011-07-22 2017-09-22 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Композиция
CA2880576A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
EP2922547B1 (en) 2012-11-20 2017-03-08 Glaxosmithkline LLC Novel compounds
BR112015011447A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto
PT2922549T (pt) 2012-11-20 2017-09-01 Glaxosmithkline Llc Novos compostos
EP3107915B1 (en) 2014-02-20 2017-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon

Also Published As

Publication number Publication date
MX358025B (es) 2018-08-02
DOP2015000121A (es) 2015-11-30
PH12015501100A1 (en) 2015-07-27
US20150284396A1 (en) 2015-10-08
HK1208826A1 (en) 2016-03-18
CA2892218A1 (en) 2014-05-30
PL2922549T3 (pl) 2017-11-30
US20180140695A1 (en) 2018-05-24
MX2015006375A (es) 2015-10-05
EP2922549A1 (en) 2015-09-30
KR20150085055A (ko) 2015-07-22
BR112015011400A8 (pt) 2019-10-01
EP2922549B1 (en) 2017-06-21
SI2922549T1 (sl) 2017-10-30
JP6228223B2 (ja) 2017-11-08
SG11201503282RA (en) 2015-06-29
PH12015501100B1 (en) 2015-07-27
RS56233B1 (sr) 2017-11-30
US9540383B2 (en) 2017-01-10
HRP20171150T1 (hr) 2017-10-06
CN104780922B (zh) 2016-09-07
US20170080085A1 (en) 2017-03-23
BR112015011400A2 (pt) 2017-07-11
CN104780922A (zh) 2015-07-15
UA114645C2 (uk) 2017-07-10
ES2639789T3 (es) 2017-10-30
EA028480B1 (ru) 2017-11-30
CR20150268A (es) 2015-07-01
AU2013348218A1 (en) 2015-06-04
DK2922549T3 (en) 2017-09-11
HUE13857477T2 (hu) 2018-05-28
LT2922549T (lt) 2017-09-11
EP2922549A4 (en) 2016-04-06
AU2013348218B2 (en) 2016-10-13
IL238800B (en) 2018-10-31
CY1119557T1 (el) 2018-03-07
CL2015001342A1 (es) 2015-10-02
PT2922549T (pt) 2017-09-01
WO2014081645A1 (en) 2014-05-30
IL238800A0 (en) 2015-06-30
PE20151086A1 (es) 2015-08-20
US9907847B2 (en) 2018-03-06
ME02867B (me) 2018-04-20
NZ707319A (en) 2019-09-27
JP2016500068A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
EA201590684A1 (ru) Новые соединения
EA201590189A1 (ru) Пиразолопиримидиновые соединения
EA201100113A1 (ru) Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
EA201100114A1 (ru) Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201290631A1 (ru) Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она
CY1120866T1 (el) Παρεμποδιστες dna-pk
EA201490357A1 (ru) Индазолы
EA201100115A1 (ru) Новые производные аденина
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
NZ705360A (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IN2014MN02652A (ru)
IN2014MN02658A (ru)
BR112015011447A2 (pt) composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
IN2014MN02657A (ru)
BR112015011439A2 (pt) composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
AR074754A1 (es) Derivados de purina-8-ona
UY32356A (es) Compuestos inductores del interferón humano y sus usos
JO3094B1 (ar) مشتقات بيورين للاستخدام في علاج أمراض تحسسية والتهابية ومعدية
TH155660A (th) สารประกอบพิแรโซโลพิริมิดีน
MA37848A1 (fr) Composés pyrazolopyrimidine
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU